- LivaNova PLC reported first-quarter 2026 results showing sales of US$362.26 million, up from US$316.86 million a year earlier, with net income of US$22.29 million replacing a prior-year net loss and earnings per share turning positive.
- The swing from a very large loss per share a year ago to earnings of roughly US$0.40–US$0.41 highlights a sharp improvement in profitability and cost control across the business.
- We will now examine how LivaNova’s return to profitability in the latest quarter may reshape its investment narrative and medium-term expectations.
Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
LivaNova Investment Narrative Recap
To own LivaNova, you need to believe that its neuromodulation and cardiopulmonary franchises can translate clinical and reimbursement wins into durable earnings, despite pricing and competition pressures. The Q1 2026 return to profitability supports that thesis in the near term, but it does not remove key risks around reimbursement, R&D intensity and potential margin compression. For now, the latest quarter looks like a supportive, rather than transformational, data point for the story.
The most relevant recent announcement alongside these results is the FDA PMA approval for the aura6000 System for obstructive sleep apnea in March 2026, now backed by 12 month OSPREY data. This adds a new therapy platform just as LivaNova shows improved cost control and earnings, giving investors more to watch around execution on OSA as a potential medium term growth driver while keeping an eye on reimbursement and adoption risks.
Yet, while earnings have turned positive, investors should still be aware of how reimbursement pressures and high R&D spend could...
Read the full narrative on LivaNova (it's free!)
LivaNova's narrative projects $1.7 billion revenue and $173.6 million earnings by 2029.
Uncover how LivaNova's forecasts yield a $79.18 fair value, a 13% upside to its current price.
Exploring Other Perspectives
Some of the lowest analysts were assuming only about 5% annual revenue growth and profit margins near 11% by 2029, so compared with the recent profitability rebound and your focus on reimbursement and supplier risks, their view is much more cautious and may need rethinking after this quarter.
Explore 3 other fair value estimates on LivaNova - why the stock might be worth as much as 27% more than the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your LivaNova research is our analysis highlighting 3 key rewards that could impact your investment decision.
- Our free LivaNova research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate LivaNova's overall financial health at a glance.
Looking For Alternative Opportunities?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
- AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- The latest GPUs need a type of rare earth metal called Neodymium and there are only 30 companies in the world exploring or producing it. Find the list for free.
- The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com